ImmunoGen, Inc. (NASDAQ:IMGN) registered a -4.51% decrease, still its new closing price is 54.30% up from the company’s 1 year high of 9.78.It posted -6.05% losses in previous 5 sessions and is now the subject of 5 analysts who together assign a hold rating on stock. 1 of Wall Street analysts have an underperform rating; the 0 sells versus 3 buy or better ratings. The 9 stock analysts following this company have an average price target at $4.57, with individual PT in the $2.00-$8.50 range. The shares moved at $2.33, implying that brokerage firms see shares losing about -72.56% in twelve months time.
ImmunoGen, Inc. (IMGN) SEC Form 4 News
The stock is getting much attention these days as insiders are adding shares while they posted a 14.22% rise year to date. A Director at ImmunoGen, Inc. (IMGN) acquired shares in a transaction closed on Thursday December 15, 2016. Goldberg Mark Alan bought 20,000 shares in the company at $1.8 each and collected $36,000 in proceeds. Goldberg Mark Alan now owns 23,800 shares in the company after this transaction. A CEO in the company, Enyedy Mark J, disclosed a transaction on Tuesday November 08, 2016 that ended up paying $45,001 from the purchase of 25,000 shares at $1.83 per share.
ImmunoGen, Inc. (NASDAQ:IMGN) Upcoming Results on Tap
ImmunoGen, Inc. will next provide financial results for the September 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.37 in that period. Sales during the quarter are predicted to arrive at $12.98 million.
Earnings surprise history: Last quarter, the company posted approximately $7.66 million in revenue and EPS of $-0.47. The mean forecast was for $21.11 million and $-0.38 a share, respectively. One quarter earlier, revenue for the stock was at $7.41 million, with earnings at $-0.51/share.
ImmunoGen, Inc. (IMGN) Brokerage Update
ImmunoGen, Inc. (IMGN) is in RBC Capital Mkts’s research list so their analyst rating change is noteworthy. These shares were downgraded to Sector Perform from Outperform by RBC Capital Mkts, according to news reported on Friday April 29, 2016.Another important research note was issued by Jefferies on Wednesday November 25, 2015.The firm upgraded IMGN to Buy from Hold. Over the last six months and over the last three months, the shares of ImmunoGen, Inc. (IMGN), have changed -16.19% and 17.09%, respectively.